Latest news
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China - MorningstarMorningstar · Thu, 06 Aug 2026 17:30:00 GMTAdneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea - The Manila TimesThe Manila Times · Wed, 05 Aug 2026 12:40:24 GMTAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product - finance.yahoo.comfinance.yahoo.com · Wed, 05 Aug 2026 12:00:00 GMTAlteogen Signs New $365 Million Technology Out-Licensing Deal... "Aiming for Multiple Product Agreements in the Second Half" - asiae.co.krasiae.co.kr · Tue, 04 Aug 2026 23:17:40 GMTTVTX: Exclusive license for civorebrutinib adds $112.5M upfront, $1.03B milestones, and broad kidney pipeline - TradingViewTradingView · Tue, 04 Aug 2026 20:47:46 GMTM&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Enters Merger Agreement with Lantheus - Pharmaceutical ExecutivePharmaceutical Executive · Tue, 04 Aug 2026 14:07:34 GMTPathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMT